Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 203 posts found.

MSD image

Endocyte lung cancer drug shows promise

March 24, 2014
Research and Development, Sales and Marketing Endocyte, MSD, NSCLC, lung cancer, vintafolide

Endocyte and partner MSD have released positive mid-stage trial results for their investigational lung cancer drug vintafolide. The treatment met …

News
GSK image

GSK cancer vaccine fails again

March 20, 2014
Sales and Marketing Cancer, GSK, MAGE-A3 cancer immunotherapeutic, NSCLC, lung cancer, melanoma

GlaxoSmithKline’s MAGE-A3 cancer immunotherapeutic has delivered another late-stage blow to the firm but it still vows to continue trials.  The …

News

New online tool to hear lung cancer patients’ stories

October 29, 2013
Medical Communications, Sales and Marketing Boehringer, NSCLC, glcc, lung cancer

The Global Lung Cancer Coalition and Boehringer Ingelheim have teamed-up to increase awareness of the challenges facing individuals and families …

News
xalkori image

Price cut not enough for Pfizer’s Xalkori

August 16, 2013
Sales and Marketing NICE, Pfizer, Xalkori, lung cancer

In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …

News
Lilly image

Phoenix from the flames for Lilly cancer drug

August 14, 2013
Research and Development, Sales and Marketing NSCLC, lilly, lung cancer, necitumumab

A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …

News

Funding boost for lung cancer ‘map’

July 18, 2013
Research and Development, Sales and Marketing cancer research, lung cancer, tracerx

A new Cancer Research UK study aims to unlock lung cancer’s secrets by tracking how lung tumours develop and evolve …

News
boehringer_german_building_at_night_5

FDA approves Boehringer’s lung cancer drug

July 12, 2013
Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer

Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …

News
Tarceva image

Discount sways NICE into recommending Tarceva

May 10, 2012
Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer

NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease.  The watchdog said …

News

Roche’s Lung cancer test approved for Europe

December 5, 2011
Research and Development, Sales and Marketing Roche, Tarceva, lung cancer

A new test which should help to better target treatment of patients with non-small cell lung cancer (NSCLC) has received …

News

Cephalon buys Gemin X for $225 million

March 24, 2011
Research and Development Cephalon, lung cancer

Cephalon is to acquire oncology specialist Gemin X and gain access to its cancer candidate obatoclax. The US biopharmaceutical firm …

News
Lung cancer cells

No magic bullet, but a growing arsenal against lung cancer

February 23, 2011
Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer

A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …

Feature
Merck Serono cancer disease awareness campaign

Digital Pharma: Merck Serono launches campaign for cancer carers

February 4, 2011
Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer

Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …

News
Tarceva tablet

Roche set to challenge NICE Tarceva decision

November 25, 2010
Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer

NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …

News

Novartis drops late stage lung cancer candidate

November 11, 2010
Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer

Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …

News

Pfizer to seek US approval for crizotinib next year

November 1, 2010
Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer

Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025